Prospection, Author at Prospection

Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia

This study aimed to examine patient characteristics, persistence and adherence to treatment associated with use of second-generation antipsychotic long-acting injectable (SGA LAI) medications in the Australian real-world setting.

Prospection Earns ISO/IEC 27001 Certification!

Prospection is now officially accredited by the internationally recognised ISO standards. The ISO/IEC 27001:2013 refers to a framework of evaluation that addresses an organisation’s information security management system (ISMS). The certification demonstrates our commitment to…

Prospection is a Gold Sponsor

Drive trust in the robustness of RWD and RWE from within your organisation. Join us at Reuter’s European pharma event 11-13 October.

Japan healthcare data access agreement

Prospection announces a unique data access agreement with leading Japanese medical data company Medical Data Vision Co., Ltd. (MDV).

The Democratisation of Real-World Evidence

Real-world evidence is playing an increasingly important role in healthcare delivery.

RWD providing answers to real world questions

Real world data provides patient and disease insights. Prospection Co-founders, Eric Chung, CEO and Dr Peter Cronin, Head of Data & Partnerships, joined Techwire Asia’s, ‘Tech Means Business‘ podcast with Joe Green. Real world data…

Accelerate clinical trials with real world evidence. Prospection Partners with Novotech Health Holdings

Media Release Prospection and Novotech Partner Sydney, 25 January 2022 – Global healthcare data technology company, Prospection, and leading Asia-Pacific biotech specialist CRO, Novotech Health Holdings, announce an strategic partnership to combine the power of…

Persistence with urate-lowering therapy in Australia: A longitudinal analysis of allopurinol prescriptions

Gout is the most common form of inflammatory arthritis in men. Despite the availability of effective urate-lowering therapies (ULT), the management of gout is suboptimal due to poor persistence with ULT. This study examined national prescribing patterns of ULT to determine persistence with allopurinol in Australia.

Ibrutinib use, treatment duration, and concomitant medications in Australian patients with relapsed or refractory chronic lymphocytic leukaemia

This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general community compared to the selected trial population.

Author: Prospection